BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30187811)

  • 1. Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.
    Ziolkowska E; Wolowiec D; Karpinski P; Blonski JZ; Lech-Maranda E; Borowiec M; Balcerczak E; Sasiadek M; Robak T; Korycka-Wolowiec A
    Leuk Lymphoma; 2019 Jun; 60(6):1409-1419. PubMed ID: 30187811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro.
    Ziolkowska E; Wolowiec D; Cebula-Obrzut B; Blonski JZ; Smolewski P; Robak T; Korycka-Wolowiec A
    Postepy Hig Med Dosw (Online); 2014 Dec; 68():1433-43. PubMed ID: 25531707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
    Tinhofer I; Steurer M; Leitinger G; Rumpold H; Egle A; Erdel M; Greil R
    Haematologica; 2006 Sep; 91(9):1291-3. PubMed ID: 16956841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
    Jantus-Lewintre E; Sarsotti E; Terol MJ; Benet I; García-Conde J
    Clin Transl Oncol; 2006 Nov; 8(11):805-11. PubMed ID: 17134969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
    Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
    Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
    Chen YH; Peterson LC; Dittmann D; Evens A; Rosen S; Khoong A; Shankey TV; Forman M; Gupta R; Goolsby CL
    Am J Clin Pathol; 2007 Feb; 127(2):182-91. PubMed ID: 17210531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clonality analysis and mutation status of IgVH genes in classic Richter's syndrome].
    Mao ZR; Rosenwald A; Zhang SJ; Zhou R; Mueller-Hermelink HK
    Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):364-70. PubMed ID: 19031714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IgVH mutation status in patients with chronic lymphocytic leukemia].
    Zhang YP; Chen LJ; Zheng WJ; Wu YJ; Qiu HX; Qian SX; Xu W; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):164-7. PubMed ID: 18788614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
    Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
    Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overrepresentation of specific gene segments of expressed immunoglobulin heavy chain variable region among unmutated and mutated patients with chronic lymphocytic leukemia].
    Yu Z; Li ZJ; Yi SH; Zhou KS; Hao M; Qi JY; Li CH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):529-32. PubMed ID: 22338175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia.
    Yepes S; Torres MM; López-Kleine L
    BMC Genomics; 2015 Nov; 16():1002. PubMed ID: 26606983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenetics of chronic lymphocytic leukemia.
    Patkar N; Rabade N; Kadam PA; Mishra F; Muranjan A; Tembhare P; Chaudhary S; Joshi S; Jain H; Dangi U; Bagal B; Khattry N; Menon H; Gujral S; Sengar M; Subramanian PG
    Indian J Pathol Microbiol; 2017; 60(1):38-42. PubMed ID: 28195089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.
    Oscier DG; Gardiner AC; Mould SJ; Glide S; Davis ZA; Ibbotson RE; Corcoran MM; Chapman RM; Thomas PW; Copplestone JA; Orchard JA; Hamblin TJ
    Blood; 2002 Aug; 100(4):1177-84. PubMed ID: 12149195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.